Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 14, 2018 - Issue
Submit an article Journal homepage
168
Views
35
CrossRef citations to date
0
Altmetric
Review

Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma

Michael D Jain1 Department of Blood and Marrow Transplantation and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA;2 Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
,
Christina A Bachmeier3 Department of Pharmacy, Moffitt Cancer Center, Tampa, FL, USA
,
Vania H Phuoc2 Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA
&
Julio C Chavez2 Department of Oncologic Sciences, University of South Florida, Tampa, FL, USA;4 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USACorrespondence[email protected]
Pages 1007-1017 | Published online: 31 May 2018

Citations (35)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Huihui Zhang, Xiaofei Lv, Qunfang Kong & Yi Tan. (2022) IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Human Vaccines & Immunotherapeutics 18:1, pages 1-14.
Read now
Andreas Viardot, Verena Wais, Elisa Sala & Sixten Koerper. (2019) Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel. Cancer Management and Research 11, pages 2393-2404.
Read now

Articles from other publishers (33)

Reyad Dada. (2022) Understanding the differences in outcome between CART studies as second-line treatment in aggressive lymphoma. Journal of Oncology Pharmacy Practice 29:1, pages 183-190.
Crossref
Mariana Tannoury, Delphine Garnier, Santos A. Susin & Brigitte Bauvois. (2022) Current Status of Novel Agents for the Treatment of B Cell Malignancies: What’s Coming Next?. Cancers 14:24, pages 6026.
Crossref
Jun Liu, Yingying Mao, Qingqing Li, Zhenzhen Qiu, Jingjing Li, Xiaoxin Li, Wenhan Liang, Mingyu Xu, Andrew Li, Xiangsheng Cai, Wangsheng Wu, Huangyao Chen, Renhe Yan, Jinlong Li, Weiwang GuHongwei Li. (2022) Efficient Gene Transfer to Kidney Using a Lentiviral Vector Pseudotyped with Zika Virus Envelope Glycoprotein. Human Gene Therapy 33:23-24, pages 1269-1278.
Crossref
Semira Sheikh, Denis Migliorini & Noémie Lang. (2022) CAR T-Based Therapies in Lymphoma: A Review of Current Practice and Perspectives. Biomedicines 10:8, pages 1960.
Crossref
Ana Carolina Caballero, Laura Escribà-Garcia, Carmen Alvarez-Fernández & Javier Briones. (2022) CAR T-Cell Therapy Predictive Response Markers in Diffuse Large B-Cell Lymphoma and Therapeutic Options After CART19 Failure. Frontiers in Immunology 13.
Crossref
Nathan Denlinger, David Bond & Samantha Jaglowski. (2022) CAR T-cell therapy for B-cell lymphoma. Current Problems in Cancer 46:1, pages 100826.
Crossref
Semira Sheikh, Sepideh Mokhtari, Jeffrey A. Silverman, Kayla Reid, Rawan Faramand, Marco L. Davila, Norman Franke, Frederick L. Locke, Michael D. Jain, Daniel Wong & John G. Kuruvilla. (2021) Transverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. eJHaem 3:1, pages 223-227.
Crossref
Bushra Tbakhi & Patrick M. Reagan. (2022) Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL). Therapeutic Advances in Hematology 13, pages 204062072210807.
Crossref
Ireri Alejandra Carbajal-Valenzuela, Nuvia Marina Apolonio–Hernandez, Diana Vanesa Gutierrez-Chavez, Beatriz González-Arias, Alejandra Jimenez-Hernandez, Irineo torres-Pacheco, Enrique Rico-García, Ana Angelica Feregrino-Pérez & Ramón Gerardo Guevara-González. 2022. Biological Macromolecules. Biological Macromolecules 97 138 .
Ayana R. Kumar, Aswathy R. Devan, Bhagyalakshmi Nair, Balachandran S. Vinod & Lekshmi R. Nath. (2021) Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets. Molecular Biology Reports 48:12, pages 8075-8095.
Crossref
Forat Lutfi, Long Wu, Sarah Sunshine & Xuefang Cao. (2021) Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation. Frontiers in Immunology 12.
Crossref
Xin Li, Mei-Jing Liu, Nan Mou, Zhen-Xing Yang, Jia  Wang, Juan Mu, Hai-Bo Zhu & Qi Deng. (2021) Efficacy and safety of humanized CD19 CAR‑T as a salvage therapy for recurrent CNSL of B‑ALL following murine CD19 CAR‑T cell therapy. Oncology Letters 22:5.
Crossref
Nawid Albinger, Jessica Hartmann & Evelyn Ullrich. (2021) Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Therapy 28:9, pages 513-527.
Crossref
Zihao Chang, Ping Jian, Qiunan Zhang, Wenyi Liang, Kun Zhou, Qian Hu, Yuqi Liu, Runping Liu & Lanzhen Zhang. (2021) Tannins in Terminalia bellirica inhibit hepatocellular carcinoma growth by regulating EGFR-signaling and tumor immunity . Food & Function 12:8, pages 3720-3739.
Crossref
Andrew Pradeep, R. Sethu Nagarajan & H. Fazil. 2021. Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer. Handbook of Research on Nano-Strategies for Combatting Antimicrobial Resistance and Cancer 294 305 .
Jose Sandoval-Sus & Julio C. Chavez. (2021) The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma. Therapeutic Advances in Hematology 12, pages 204062072110177.
Crossref
Xinrong Xiang, Qiao He, Yang Ou, Wen Wang & Yu Wu. (2020) Efficacy and Safety of CAR-Modified T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma: A Meta-Analysis of Prospective Clinical Trials. Frontiers in Pharmacology 11.
Crossref
Eduardo Huarte, Roddy S. O'Connor, Michael T. Peel, Selene Nunez-Cruz, John Leferovich, Ashish Juvekar, Yan-ou Yang, Lisa Truong, Taisheng Huang, Ahmad Naim, Michael C. Milone & Paul A. Smith. (2020) Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. Clinical Cancer Research 26:23, pages 6299-6309.
Crossref
Arkadiusz Z. Dudek, Kate Baxstrom, Sushma Bharadwaj, Anne Blaes, Amit Kulkarni, Emil Lou, Vijeyaluxmy Nehru, Emma Rabinovich, Ardaman Shergill & Maya Viner. 2020. Precision Medicine in Oncology. Precision Medicine in Oncology 1 60 .
Erin A. Dean, Rahul S. Mhaskar, Hong LuMina S. Mousa, Gabriel S. Krivenko, Aleksandr Lazaryan, Christina A. Bachmeier, Julio C. ChavezTaiga Nishihori, Marco L. Davila, Farhad Khimani, Hien D. Liu, Javier Pinilla-IbarzBijal D. ShahMichael D. Jain, Yoganand Balagurunathan & Frederick L. Locke. (2020) High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances 4:14, pages 3268-3276.
Crossref
Daniela Enriquez-Ochoa, Pedro Robles-Ovalle, Karla Mayolo-Deloisa & Marion E. G. Brunck. (2020) Immobilization of Growth Factors for Cell Therapy Manufacturing. Frontiers in Bioengineering and Biotechnology 8.
Crossref
Changju Qu, Nana Ping, Liqing Kang, Hailing Liu, Songbin Qin, Qian Wu, Xiaochen Chen, Meng Zhou, Fan Xia, Aihua Ye, Danqing Kong, Caixia Li, Lei Yu, Depei Wu & Zhengming Jin. (2020) Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden. Journal of Immunotherapy 43:1, pages 32-37.
Crossref
Stefan Worgall & Ronald G. Crystal. 2020. Principles of Tissue Engineering. Principles of Tissue Engineering 493 518 .
Uwe Fricke, Lutz Hein & Ulrich Schwabe. 2020. Arzneiverordnungs-Report 2020. Arzneiverordnungs-Report 2020 43 150 .
Theresa Pesch, Lucia Bonati, William Kelton, Cristina Parola, Roy A. Ehling, Lucia Csepregi, Daisuke Kitamura & Sai T. Reddy. (2019) Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells. Frontiers in Immunology 10.
Crossref
Britten, Ragusa, Tosi & Kamel. (2019) MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?. Cells 8:11, pages 1341.
Crossref
Aimen K. Aljoundi, Clement Agoni, Fisayo A. Olotu & Mahmoud E.S. Soliman. (2019) Turning to Computer-aided Drug Design in the Treatment of Diffuse Large B-cell Lymphoma: Has it been Helpful?. Anti-Cancer Agents in Medicinal Chemistry 19:11, pages 1325-1339.
Crossref
Lori Davis & Frank Park. (2019) Gene therapy research for kidney diseases. Physiological Genomics 51:9, pages 449-461.
Crossref
Fernando Aranda, Miguel Barajas & Eduardo Huarte. (2019) Transgenic Tumor Models for Evaluating CAR T‐Cell Immunotherapies. Current Protocols in Pharmacology 86:1.
Crossref
Anna Dushenkov & Paiboon Jungsuwadee. (2019) Chimeric antigen receptor T-cell therapy: Foundational science and clinical knowledge for pharmacy practice. Journal of Oncology Pharmacy Practice 25:5, pages 1217-1225.
Crossref
Noopur RajeJesus BerdejaYi LinDavid Siegel, Sundar JagannathDeepu MadduriMichaela LiedtkeJacalyn RosenblattMarcela V. MausAshley TurkaLyh-Ping LamRichard A. MorganKevin FriedmanMonica MassaroJulie WangGreg RussottiZhihong YangTimothy CampbellKristen HegeFabio PetroccaM. Travis QuigleyNikhil MunshiJames N. Kochenderfer. (2019) Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine 380:18, pages 1726-1737.
Crossref
Adam Levin & Nirav N. Shah. (2019) Chimeric antigen receptor modified T cell therapy in B cell non‐Hodgkin lymphomas. American Journal of Hematology 94:S1, pages S18-S23.
Crossref
Ashley Cooney, Paul McCrayJr.Jr. & Patrick Sinn. (2018) Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward. Genes 9:11, pages 538.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.